Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene methylation in thyroid tumorigenesis.

Mingzhao Xing1

  • 1Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, MD 21287, USA. mxing1@jhmi.edu

Endocrinology
|September 2, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Performance Asymmetric Supercapacitors Assembled from La-Doped ZnCo<sub>2</sub>O<sub>4</sub>/MnCo-LDH Nanoflower Positive Electrodes and Ti-Supported Sb-Doped SnO<sub>2</sub> Negative Electrodes.

Micromachines·2026
Same author

A targeted proteomics assay for the preoperative diagnosis of thyroid nodules.

Cell reports. Medicine·2026
Same author

Functional Loss of the Tumor Suppressor Gene <i>RASAL1</i> Through Formation of Aberrant Splice Variant <i>RASAL1-004</i> as a Novel Oncogenic Mechanism in Thyroid Cancer.

Thyroid : official journal of the American Thyroid Association·2025
Same author

Tumour genetics and thyroid cancer staging.

The Lancet. Oncology·2025
Same author

Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study.

The Lancet. Oncology·2025
Same author

Higher Distressed Communities Index is associated with more aggressive features in papillary thyroid cancer.

American journal of surgery·2025
Same journal

Zingerone ameliorates ovarian impairment by regulating steroidogenesis and apoptosis in letrozole-treated mouse.

Endocrinology·2026
Same journal

Loss of the calorie restriction response protein DEPP1 worsens diet-induced obesity.

Endocrinology·2026
Same journal

Long Non-Coding RNAs Mediate Endocrine Signaling and Resistance in Prostate Cancer.

Endocrinology·2026
Same journal

Repeated Chemogenetic Activation of C1 Catecholamine Neurons Reduces Subsequent Glucoprivic Responses and Mimics HAAF.

Endocrinology·2026
Same journal

Postnatal exposure to maternal hypothyroidism leads to developmental delay and metabolic dysregulations in male mice.

Endocrinology·2026
Same journal

Discovery proteomics identification of factors contributing to gonadotropin β expression.

Endocrinology·2026
See all related articles

Aberrant gene methylation is crucial in thyroid cancer development, affecting tumor suppressor and thyroid-specific genes. This epigenetic change can impact treatment outcomes and offers potential therapeutic targets.

Area of Science:

  • Epigenetics
  • Molecular Oncology
  • Thyroid Cancer Research

Background:

  • Aberrant gene methylation is a key epigenetic event in human tumorigenesis, particularly in thyroid cancer.
  • Methylation of tumor suppressor genes can occur early in thyroid tumor development, even in benign stages.
  • Specific gene methylation patterns are associated with distinct thyroid cancer subtypes and signaling pathways.

Purpose of the Study:

  • To investigate the role of aberrant gene methylation in thyroid tumorigenesis.
  • To explore the association between gene methylation, thyroid cancer types, and signaling pathways.
  • To understand the impact of gene methylation on radioiodine treatment failure in thyroid cancer.

Main Methods:

  • Analysis of gene methylation patterns in thyroid tumors.

Related Experiment Videos

  • Correlation of methylation status with specific thyroid cancer subtypes.
  • Investigation of methylation's link to signaling pathways like PI3K/Akt and BRAF/MAPK.
  • Assessment of methylation in thyroid-specific genes and its effect on radioiodine therapy.

    • Main Results:

    • Methylation of PTEN and RASSF1A is prevalent in follicular thyroid cancer, linked to the PI3K/Akt pathway.
    • Methylation of TIMP3, SLC5A8, and DAPK is observed in papillary thyroid cancer, associated with the BRAF/MAPK pathway.
    • Methylation and silencing of thyroid-specific genes (NIS, TSHR) are common in thyroid cancer, contributing to radioiodine treatment failure.

    Conclusions:

    • Aberrant gene methylation is a significant factor in thyroid tumorigenesis and influences specific cancer subtypes and pathways.
    • Methylation of thyroid-specific genes contributes to radioiodine therapy resistance.
    • Further research into epigenetic mechanisms, including histone modifications, is needed for novel therapeutic targets in thyroid cancer.